- Home
- IDE vs BIOA Comparison
IDE vs BIOA Comparison
Compare IDE & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDE
- BIOA
- Stock Information
- Founded
- IDE 2010
- BIOA 2015
- Country
- IDE United States
- BIOA United States
- Employees
- IDE N/A
- BIOA N/A
- Industry
- IDE Finance/Investors Services
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- IDE Finance
- BIOA Health Care
- Exchange
- IDE Nasdaq
- BIOA Nasdaq
- Market Cap
- IDE 177.2M
- BIOA 153.4M
- IPO Year
- IDE N/A
- BIOA 2024
- Fundamental
- Price
- IDE $11.59
- BIOA $4.65
- Analyst Decision
- IDE
- BIOA Hold
- Analyst Count
- IDE 0
- BIOA 4
- Target Price
- IDE N/A
- BIOA $5.67
- AVG Volume (30 Days)
- IDE 33.5K
- BIOA 313.1K
- Earning Date
- IDE 01-01-0001
- BIOA 08-15-2025
- Dividend Yield
- IDE 8.83%
- BIOA N/A
- EPS Growth
- IDE N/A
- BIOA N/A
- EPS
- IDE N/A
- BIOA N/A
- Revenue
- IDE N/A
- BIOA $1,451,000.00
- Revenue This Year
- IDE N/A
- BIOA N/A
- Revenue Next Year
- IDE N/A
- BIOA N/A
- P/E Ratio
- IDE N/A
- BIOA N/A
- Revenue Growth
- IDE N/A
- BIOA N/A
- 52 Week Low
- IDE $8.61
- BIOA $2.88
- 52 Week High
- IDE $10.46
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- IDE 63.98
- BIOA N/A
- Support Level
- IDE $11.30
- BIOA N/A
- Resistance Level
- IDE $11.74
- BIOA N/A
- Average True Range (ATR)
- IDE 0.08
- BIOA 0.00
- MACD
- IDE -0.02
- BIOA 0.00
- Stochastic Oscillator
- IDE 79.55
- BIOA 0.00
About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.